- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06766396
Predictors of PPIUCD Discontinuation at Two Years: A Clinical Study in Pakistan
Predictors for Discontinuation of Post Placental Intrauterine Contraceptive Device (PPIUCD) at Two-year Point With Implications for Population Stabilization in Pakistan
Study Overview
Status
Intervention / Treatment
Detailed Description
This prospective cohort study was conducted in the Department of Obstetrics and Gynecology at Services Hospital, Lahore, Pakistan, from November 2017 to December 31, 2022, after receiving ethical approval from the Institutional Review Board (Ref No. IRB/2017/373/SIMS). The study aimed to evaluate the continuation rates, complications, and satisfaction associated with postpartum intrauterine contraceptive devices (PPIUCDs) as a method of long-acting reversible contraception (LARC). The Government of Punjab provided contraceptive supplies free of cost to support the study.
Pregnant women attending antenatal care were recruited for the study after being educated about the importance of contraception using the GATHER counseling technique. Women who expressed interest in LARC, including PPIUCD, were provided detailed information about its benefits and risks. Informed consent was obtained, and their socio-demographic data were documented using a structured questionnaire. Willingness to participate was noted by stamping the antenatal cards of consenting women.
PPIUCDs were inserted immediately postpartum for both vaginal and cesarean deliveries. For vaginal deliveries, Kelly's forceps were used under aseptic conditions. During cesarean deliveries, PPIUCDs were inserted before the uterine incision was closed. All insertions were performed by healthcare providers trained by master trainers to ensure standardized techniques and minimize complications. Each participant received a follow-up card containing information about potential issues, such as irregular bleeding or difficulty in feeling the thread, and instructions to report these problems promptly.
The structured questionnaire developed for the study captured key socio-demographic and clinical information, including age, parity, education, occupation, monthly income, family size, and access to smartphones or Wi-Fi. Data on prior contraceptive use, reasons for non-use (e.g., myths or religious beliefs), and motivations for choosing PPIUCD (e.g., convenience, family influence, or doctor counseling) were also collected.
Participants were followed up at 3 months, 6 months, 1 year, and 2 years after insertion, either through in-person visits or telephonic interviews. During these follow-ups, data on complications such as irregular or heavy menstrual bleeding, pelvic pain, vaginal discharge, or device expulsion were recorded. Women were asked about their satisfaction with PPIUCD use and whether they continued or discontinued the method. For those who reported issues, a speculum examination was offered to check the thread position and trim it if necessary. Detailed information about device removal or expulsion, including the timing and reasons, was also collected during follow-ups.
The primary outcome of the study was the continuation rate at 24 months, defined as the probability of women consistently using the PPIUCD during this period. Secondary outcomes included reasons for discontinuation, and complications experienced.
Data analysis was performed using SPSS version 23. Qualitative variables were expressed as proportions with 95% confidence intervals (CIs). Comparative analyses between groups were conducted using the Chi-square test or Fisher's Exact test, depending on the data characteristics. A p-value of ≤ 0.05 was considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- Services Institute of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant women attending antenatal care at the Department of Obstetrics and Gynecology, Services Hospital Lahore.
- Willing to use postpartum intrauterine contraceptive device (PPIUCD) as a method of contraception.
- Provided informed consent for participation in the study.
- Delivered via vaginal delivery or cesarean section with no contraindications to PPIUCD insertion.
Exclusion Criteria:
- Known uterine anomalies or severe uterine bleeding post-delivery.
- Diagnosed with chorioamnionitis or puerperal sepsis during delivery or postpartum.
- Known hypersensitivity or contraindications to copper-based intrauterine devices.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Postpartum Intrauterine Contraceptive Device (PPIUCD) Insertion
Participants in this arm will receive the intervention of a postpartum intrauterine contraceptive device (PPIUCD) insertion.
The PPIUCD will be inserted immediately postpartum for vaginal deliveries using Kelly's forceps under aseptic conditions or during cesarean section prior to uterine incision closure.
All insertions will be performed by trained healthcare professionals to ensure consistency.
Participants will be followed prospectively for up to 24 months to assess continuation rates, complications, and satisfaction with the method.
|
Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery.
For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure.
All insertions will be performed by trained healthcare professionals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
continuation rate of PPIUCD at 24 months.
Time Frame: 24 months post-insertion
|
The percentage of participants who continue using the postpartum intrauterine contraceptive device (PPIUCD) at 24 months after insertion.
|
24 months post-insertion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication Rate Associated with PPIUCD Use
Time Frame: From insertion to 24 months post-insertion
|
The percentage of participants reporting complications such as heavy or irregular menstrual bleeding, expulsion, pelvic pain, or vaginal discharge during the follow-up period.
|
From insertion to 24 months post-insertion
|
|
Reasons for PPIUCD Discontinuation
Time Frame: From insertion to 24 months post-insertion
|
Documenting reasons for PPIUCD removal, including complications, misplaced ,wants another pregnancy or family pressures.
|
From insertion to 24 months post-insertion
|
|
Expulsion Rate of PPIUCD
Time Frame: From insertion to 24 months post-insertion
|
The percentage of participants experiencing spontaneous expulsion of the PPIUCD during the follow-up period.
|
From insertion to 24 months post-insertion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tayyiba Wasim, FCPS, Services Institute of Medical Sciences, Pakistan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB/2017/373/SIMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Contraception
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States
-
Cairo UniversityRecruiting
-
University of North Carolina, Chapel HillSociety of Family PlanningCompletedPostpartum ContraceptionUnited States
-
St. Paul's Hospital Millennium Medical College,...Not yet recruitingPostpartum ContraceptionEthiopia
-
Icahn School of Medicine at Mount SinaiTeva Pharmaceuticals USACompletedContraception | PostpartumUnited States
-
United States Naval Medical Center, PortsmouthWithdrawnContraception | Postpartum PeriodUnited States
-
University of WashingtonUniversity of Nairobi; Kenyatta National HospitalCompletedContraception | Postpartum PeriodKenya
-
University of North Carolina, Chapel HillCompletedContraception | Postpartum | AdolescenceUnited States
-
Osmaniye Korkut Ata UniversityMersin UniversityCompletedHealth Attitude | Contraception | PostpartumTurkey
-
Stanford UniversityCompletedPostpartum Contraception | Family PlanningUnited States
Clinical Trials on Postpartum Intrauterine Contraceptive Device (PPIUCD).
-
Assiut UniversityNot yet recruitingQuality of Life
-
Wenzhou Medical UniversityCompleted
-
Lundquist Institute for Biomedical Innovation at...Completed
-
Yuqing ChenCompleted
-
Fundació Institut de Recerca de l'Hospital de la...BayerCompleted
-
University of British ColumbiaTerminatedInduced Abortion
-
University of British ColumbiaTerminated
-
University of ChicagoUniversity of Illinois at ChicagoCompletedContraceptionUnited States
-
University of OklahomaCompleted